Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 211

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 211
---
 strategies involve costly activities that are susceptible to failure, and, therefore, we may not be able to generate
sufficient revenue to support and sustain our business or reach the level of sales and revenues necessary to achieve and sustain profitability.

We may not receive sufficient revenue to fund
our operations and recover our development costs. 

Our business plan involves the
sale and marketing of FDA-approved products, compounded formulations and drug candidates through third-party wholesaler and pharmacy
channels and our ImprimisRx facilities. We have limited experience selling FDA-approved products, and we may be unable to successfully
manage this business or generate sufficient revenue to recover our development costs and operational expenses. We may have only limited
success in marketing and selling our products. Although we have established and plan to grow our internal sales teams to market and sell
our products, we have limited experience with such activities and may not be able to generate sufficient physician and patient interest
in our products to generate significant revenue from sales of these products.

We may fail to realize the anticipated benefits
of our recent and any future product acquisitions.

The success of our product
acquisitions will depend on, among other things, our ability to integrate the products into our commercial platform, transfer the
products NDAs, maintain and obtain sufficient payor reimbursement coverage, maintain an adequate supply of the products, market the
products to our existing customers and re-introduce TRIESENCE to the ophthalmic market. If we experience difficulties with the
implementation of plans with respect to our acquisitions, the anticipated benefits of recent or future acquisitions may not be
realized fully or at all, or may take longer to realize than expected. Integration efforts will also divert management’s
attention and resources. These matters could have an adverse effect during any transition period and for an undetermined period
after completion of the acquisitions.

We may not be able to correctly estimate our
future operating expenses, which could lead to cash shortfalls.

The estimates of our future
operating and capital expenditures are based upon our current business plan, our current operations and our current expectations
regarding the commercialization of our proprietary formulations. Our projections have varied significantly from actual performance
in the past as a result of changes to our business model, strategy and acquisitions. We may not accurately estimate the potential
revenues and expenses of our operations. If we are unable to correctly estimate the amount of cash necessary to fund our business,
we could spend our available financial resources much faster than we expect. If we do not have sufficient funds to continue